Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 PROSTVAC-V/F with or without GM-CSF in metastatic castration-resistant prostate cancer
NL-OMON41305Phase 3Active, not recruiting
- Sponsor
- Bavarian Nordic
- Start
- May 2014
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing PROSTVAC-V/F plus GM-CSF, PROSTVAC-V/F alone and Placebo control (3 arms). Primary endpoint: Overall survival. Started May 2014; status: active, not recruiting.
02
Drugs
PROSTVAC-TRICOMsargramostim
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON41305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41305.